SECURITIES AND EXCHANGE COMMISSION
Washington, D. C. 20549
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 or 15(d) of the
Securities Exchange Act of 1934
Date of Report (Date of earliest event reported): January 6, 2000
LabOne, Inc.
----------------------------------------------------
(Exact name of registrant as specified in its charter)
Missouri 0-16946 43-1039532
-------------------- ----------- ---------------
(State or other jurisdiction (Commission (I. R. S. Employer
of incorporation) File Number) Identification No.)
10101 Renner Blvd., Lenexa, KS 66219
---------------------------------------- -------
(Address of principal executive offices) (Zip Code)
Registrant's telephone number, including area code: 913-888-1770
------------
Page 1 of 2
Item 5. Other Events
LabOne, Inc. announced that Robert D. Thompson, executive vice president,
chief operating officer and chief financial officer has resigned from the
company effective January 24, 2000, to become CEO and president of Epitope,
Inc., a medical device and diagnostic product company.
Last year, LabOne tested more than 800,000 oral fluid specimens, and is
Epitope's largest customer in the insurance testing market. In addition to
insurance, LabOne is working with STC Technologies and Epitope on the
commercial launch of the only laboratory oral fluid drugs of abuse product in
the marketplace.
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the
registrant has duly caused this report to be signed on its behalf by the
undersigned thereunto duly authorized.
LabOne, Inc.
Date: January 10, 2000 By /s/ Kurt E. Gruenbacher
------------------------
Kurt E. Gruenbacher, V.P. Finance, CAO
and Treasurer
Date: January 10, 2000 By /s/ W. Thomas Grant
------------------------
W. Thomas Grant, Chairman, President
and Chief Executive Officer
Page 2